BRUSSELS (dpa-AFX) - Swiss biopharmaceutical company Actelion Ltd. (ALIOF.PK) said that its shareholders approved all of the Board's proposals, including the Annual Report 2015 as well as the Statutory and the Consolidated Financial Statements for 2015.
A proposal by the Board to distribute a dividend out of legal reserve originating from capital contribution in the amount of CHF 1.50 per registered share was passed by shareholders. The ex-dividend date will be 9 May 2016 and the payment will be made on 11 May 2016.
Shareholders endorsed the 2015 compensation report by way of consultative vote.
Shareholders also approved the aggregate maximum compensation for the Board of Directors (Non-Executive Directors) for the term until the AGM 2017 and the aggregate compensation amount for the Actelion Executive Committee (AEC) for the financial year 2017.
The shareholders granted discharge to all members of the Board of Directors and of the Executive Management and re-elected all members of the Board which stood for election for a term of office until the conclusion of the AGM 2017.
In addition, the shareholders elected Mr. Jean-Pierre Garnier as Chairperson of the Board and Ms. Herna Verhagen, Mr. Jean-Pierre Garnier, and Mr. John J. Greisch (Chair) to the Compensation Committee.
Following the AGM, the Board of Directors of Actelion comprises a total of 10 members: Jean-Pierre Garnier (Chairman), Juhani Anttila, Robert Bertolini, Jean-Paul Clozel, John J. Greisch, Peter Gruss, Michael Jacobi, Jean Malo, David Stout and Herna Verhagen.
BDO AG, represented by Mr. Marc Schaffner, was elected as Independent Proxy for a term of office until the conclusion of the AGM 2017.
Ernst & Young was re-elected as the company's statutory auditors for the business year 2016.
Copyright RTT News/dpa-AFX